{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:34:30Z","timestamp":1722321270075},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13318-018-0471-0","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T08:29:08Z","timestamp":1521534548000},"page":"509-531","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Pharmacokinetics and Drug\u2013Drug Interactions of Elbasvir\/Grazoprevir"],"prefix":"10.1007","volume":"43","author":[{"given":"Tony K. L.","family":"Kiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2146\/ajhp160558","volume":"74","author":"LR Karaoui","year":"2017","unstructured":"Karaoui LR, Mansour H, Chahine EB. Elbasvir-grazoprevir: a new direct-acting antiviral combination for hepatitis C. Am J Health Syst Pharm. 2017;74:1533\u201340.","journal-title":"Am J Health Syst Pharm"},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.13633","volume":"43","author":"A Majumdar","year":"2016","unstructured":"Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2015\/692408","volume":"29","author":"RP Myers","year":"2015","unstructured":"Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015;29:19\u201334.","journal-title":"Can J Gastroenterol Hepatol."},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40265-017-0739-8","volume":"77","author":"ZT Al-Salama","year":"2017","unstructured":"Al-Salama ZT, Deeks ED. Elbasvir\/Grazoprevir: a review in chronic HCV genotypes 1 and 4. Drugs. 2017;77:911\u201321.","journal-title":"Drugs."},{"key":"471_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/17425255.2016.1148685","volume":"12","author":"N Sulejmani","year":"2016","unstructured":"Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016;12:353\u201361.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"471_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1517\/14656566.2016.1161028","volume":"17","author":"L Alric","year":"2016","unstructured":"Alric L, Bonnet D. Grazoprevir\u2009+\u2009elbasvir for the treatment of hepatitis C virus infection. Expert Opin Pharmacother. 2016;17:735\u201342.","journal-title":"Expert Opin Pharmacother"},{"key":"471_CR7","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12\u00a0weeks versus 18\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075\u201386.","journal-title":"Lancet"},{"key":"471_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1\u201313.","journal-title":"Ann Intern Med"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 8\u00a0weeks versus 12\u00a0weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087\u201397.","journal-title":"Lancet"},{"key":"471_CR10","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319\u201327.","journal-title":"Lancet HIV."},{"key":"471_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/cid\/civ722","volume":"62","author":"M Buti","year":"2016","unstructured":"Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62:32\u20136.","journal-title":"Clin Infect Dis"},{"key":"471_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","volume":"63","author":"X Forns","year":"2015","unstructured":"Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63:564\u201372.","journal-title":"J Hepatol"},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","volume":"2","author":"A Bruchfeld","year":"2017","unstructured":"Bruchfeld A, Roth D, Martin P, Nelson DR, Pol S, Londono MC, Monsour H Jr, Silva M, Hwang P, Arduino JM, Robertson M, Nguyen BY, Wahl J, Barr E, Greaves W. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585\u201394.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"471_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londono MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537\u201345.","journal-title":"Lancet"},{"key":"471_CR15","unstructured":"European Medicines Agency AR. Zepatier (elbasvir\/grazoprevir) Assessment Report. European Medicines Agency. 2016;EMEA\/H\/C\/004126\/0000:1-151. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004126\/WC500211237.pdf . Accessed 11 Jan 2018."},{"key":"471_CR16","unstructured":"Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics Review. 505(b)(1) New Drug Application, Priority Review (Zepatier, 100\u00a0mg grazoprevir and 50\u00a0mg elbasvir, application # 208261Orig1s000) ( https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208261Orig1s000ClinPharmR.pdf ). 2015;3838940:1-323. Accessed 11 Jan 2018."},{"key":"471_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1515\/jtim-2017-0007","volume":"5","author":"A Geddawy","year":"2017","unstructured":"Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. J Transl Int Med. 2017;5:8\u201317.","journal-title":"J Transl Int Med."},{"key":"471_CR18","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/2050640616678151","volume":"5","author":"EJ Smolders","year":"2017","unstructured":"Smolders EJ, Berden FA, de Kanter CT, Kievit W, Drenth JP, Burger DM. The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions. United Eur Gastroenterol J. 2017;5:648\u201357.","journal-title":"United Eur Gastroenterol J."},{"key":"471_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-2113-8","volume-title":"Pharmacokinetic and pharmacodynamic drug interactions associated with antiretroviral drugs","author":"TK Kiang","year":"2016","unstructured":"Kiang TK, Wilby KJ, Ensom MH. Pharmacokinetic and pharmacodynamic drug interactions associated with antiretroviral drugs. 1st ed. Singapore: ADIS; 2016.","edition":"1"},{"key":"471_CR20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-10527-7","volume-title":"Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials","author":"TK Kiang","year":"2015","unstructured":"Kiang TK, Wilby KJ, Ensom MH. Clinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials. 1st ed. Switzerland: ADIS; 2015.","edition":"1"},{"key":"471_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40262-013-0110-5","volume":"53","author":"TK Kiang","year":"2014","unstructured":"Kiang TK, Wilby KJ, Ensom MH. Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet. 2014;53:141\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40262-013-0053-x","volume":"52","author":"TK Kiang","year":"2013","unstructured":"Kiang TK, Wilby KJ, Ensom MH. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet. 2013;52:487\u2013510.","journal-title":"Clin Pharmacokinet"},{"key":"471_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pharmthera.2004.10.013","volume":"106","author":"TK Kiang","year":"2005","unstructured":"Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005;106:97\u2013132.","journal-title":"Pharmacol Ther"},{"key":"471_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/cts.12465","volume":"10","author":"HP Feng","year":"2017","unstructured":"Feng HP, Vaddady P, Guo Z, Liu F, Panebianco D, Levine V, Caro L, Butterton JR, Iwamoto M, Yeh WW. No pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir\/grazoprevir and famotidine or pantoprazole. Clin Transl Sci. 2017;10:360\u20135.","journal-title":"Clin Transl Sci."},{"key":"471_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci. 2006;94:261\u201371.","journal-title":"Toxicol Sci"},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/03602530903210716","volume":"42","author":"JO Miners","year":"2010","unstructured":"Miners JO, Mackenzie PI, Knights KM. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev. 2010;42:196\u2013208.","journal-title":"Drug Metab Rev"},{"key":"471_CR27","doi-asserted-by":"publisher","unstructured":"Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW. Pharmacokinetics, safety, and tolerability of single-dose elbasvir in participants with hepatic impairment. Eur J Drug Metab Pharmacokinet. 2017. https:\/\/doi.org\/10.1007\/s13318-017-0451-9 (Epub ahead of print).","DOI":"10.1007\/s13318-017-0451-9"},{"key":"471_CR28","doi-asserted-by":"publisher","first-page":"e00813","DOI":"10.1128\/AAC.00813-17","volume":"61","author":"L Caro","year":"2017","unstructured":"Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW. Effect of hepatic impairment on the pharmacokinetics of grazoprevir, a hepatitis C virus protease inhibitor. Antimicrob Agents Chemother. 2017;61:e00813\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"471_CR29","unstructured":"United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: clinical drug interaction studies\u2014study design, data analysis, and clinical implications, guidance for industry; 2017. pp. 1\u201332.\u00a0 https:\/\/www.fda.gov\/drugs\/ucm292362 . Accessed 11 Jan 2018."},{"key":"471_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"YY Lau","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194\u2013204.","journal-title":"Clin Pharmacol Ther"},{"key":"471_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/00498250903509375","volume":"40","author":"P Annaert","year":"2010","unstructured":"Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010;40:163\u201376.","journal-title":"Xenobiotica"},{"key":"471_CR32","unstructured":"Kiang TK, Ensom MH. Immunosuppressants. In: Beringer PE, editor. Basic clinical pharmacokinetics. 6th ed. Wolters Kluwer; 2017, p. 320\u2013357."},{"key":"471_CR33","unstructured":"Kiang TK, Ensom MH. Anti-rejection drugs. In: Murphy JE, editor. Clinical Pharmacokinetics. 6th ed: American Society of Health-System Pharmacists; 2017. p. 205\u2013220."},{"key":"471_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1124\/jpet.116.232066","volume":"357","author":"H Shen","year":"2016","unstructured":"Shen H, Dai J, Liu T, Cheng Y, Chen W, Freeden C, Zhang Y, Humphreys WG, Marathe P, Lai Y. Coproporphyrins I and III as functional markers of OATP1B activity. In vitro and in vivo evaluation in preclinical species. J Pharmacol Exp Ther. 2016;357:382\u201393.","journal-title":"J Pharmacol Exp Ther"},{"key":"471_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00228-017-2216-4","volume":"73","author":"WL Marshall","year":"2017","unstructured":"Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O\u2019Reilly TE, Butterton JR, Yeh WW. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel. Eur J Clin Pharmacol. 2017;73:593\u2013600.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0471-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:59:08Z","timestamp":1693591148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0471-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0471-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"20 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"There are no conflicts of interests declared by the author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funding was received for the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}